We sought to determine whether SHLD2 may contribute to the outcome of BC by interrogating two distinct patient‐based cohorts of triple negative breast cancer (TNBC) and basal‐like BC. The gene discussed is SHLD2; the disease is triple-negative breast carcinoma.